Article
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
Nature cancer - 1 Oct 2022
Gruber Joshua J, Afghahi Anosheh, Timms Kirsten, DeWees Alyssa, Gross Wyatt, Aushev Vasily N, Wu Hsin-Ta, Balcioglu Mustafa, Sethi Himanshu, Scott Danika, Foran Jessica, McMillan Alex, Ford James M, Telli Melinda L
Abstract excerpt
Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (gBRCA1/2)-mutant advanced breast cancer, but its activity beyond gBRCA1/2 is poorly understood. We conducted Talazoparib Beyond BRCA ( NCT02401347 ), an open-label phase II trial, to evaluate talazoparib in patients with pretreated advanced HER2-negative breast cancer (n = 13) or other solid tumors (n = 7) with mutations in homologous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.